Implantable system for treprostinil: a real-world patient experience study
Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894020907881 |
| _version_ | 1818237444067164160 |
|---|---|
| author | Shelley Shapiro Robert C. Bourge Patti Pozella David F. Harris Erick H. Borg Andrew C. Nelsen |
| author_facet | Shelley Shapiro Robert C. Bourge Patti Pozella David F. Harris Erick H. Borg Andrew C. Nelsen |
| author_sort | Shelley Shapiro |
| collection | DOAJ |
| description | Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed and is associated with a low rate of complications (United Therapeutics (Research Triangle Park, NC) in collaboration with Medtronic, Inc. (Mounds View, MN)). The current real-world experience study evaluated pulmonary arterial hypertension patients' perceptions of their quality of life, ability to perform activities of daily living, perceptions on the benefits and risks of the implantable system, and their social interactions before and after receiving the implantable system. Pulmonary arterial hypertension patients who had been transitioned from an external infusion pump to the implantable system completed a mix of quantitative and qualitative questions administered online over the course of a six-day period. A total of 20 patients completed the study. All patients reported that their quality of life, confidence out in public, and ability to travel long distances had improved. Over 90% of patients reported that their overall level of independence was better since receiving the implantable system, and most patients indicated that their ability to independently perform specific activities of daily living had improved. Responses to the qualitative questions suggested that the implantable system saved time, improved interpersonal relationships, and increased freedom. Results from this real-world patient experience study suggest this novel delivery system provides improvements in factors that are of substantial importance to patients. |
| first_indexed | 2024-12-12T12:25:51Z |
| format | Article |
| id | doaj.art-003d044438e34eb695c5ad4e3dcdc87f |
| institution | Directory Open Access Journal |
| issn | 2045-8940 |
| language | English |
| last_indexed | 2024-12-12T12:25:51Z |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj.art-003d044438e34eb695c5ad4e3dcdc87f2022-12-22T00:24:33ZengWileyPulmonary Circulation2045-89402020-04-011010.1177/2045894020907881Implantable system for treprostinil: a real-world patient experience studyShelley Shapiro0Robert C. Bourge1Patti Pozella2David F. Harris3Erick H. Borg4Andrew C. Nelsen5VA Greater Los Angeles Healthcare System Cardiology Section, David Geffen UCLA School of Medicine, UCLA Medical Center Department of Pulmonary Critical Care, Los Angeles, CA, USADepartment of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USAUnited Therapeutics Corporation, Research Triangle Park, NC, USAInsight & Measurement, LLC, Durham, NC, USAUnited Therapeutics Corporation, Research Triangle Park, NC, USAUnited Therapeutics Corporation, Research Triangle Park, NC, USAParenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed and is associated with a low rate of complications (United Therapeutics (Research Triangle Park, NC) in collaboration with Medtronic, Inc. (Mounds View, MN)). The current real-world experience study evaluated pulmonary arterial hypertension patients' perceptions of their quality of life, ability to perform activities of daily living, perceptions on the benefits and risks of the implantable system, and their social interactions before and after receiving the implantable system. Pulmonary arterial hypertension patients who had been transitioned from an external infusion pump to the implantable system completed a mix of quantitative and qualitative questions administered online over the course of a six-day period. A total of 20 patients completed the study. All patients reported that their quality of life, confidence out in public, and ability to travel long distances had improved. Over 90% of patients reported that their overall level of independence was better since receiving the implantable system, and most patients indicated that their ability to independently perform specific activities of daily living had improved. Responses to the qualitative questions suggested that the implantable system saved time, improved interpersonal relationships, and increased freedom. Results from this real-world patient experience study suggest this novel delivery system provides improvements in factors that are of substantial importance to patients.https://doi.org/10.1177/2045894020907881 |
| spellingShingle | Shelley Shapiro Robert C. Bourge Patti Pozella David F. Harris Erick H. Borg Andrew C. Nelsen Implantable system for treprostinil: a real-world patient experience study Pulmonary Circulation |
| title | Implantable system for treprostinil: a real-world patient experience study |
| title_full | Implantable system for treprostinil: a real-world patient experience study |
| title_fullStr | Implantable system for treprostinil: a real-world patient experience study |
| title_full_unstemmed | Implantable system for treprostinil: a real-world patient experience study |
| title_short | Implantable system for treprostinil: a real-world patient experience study |
| title_sort | implantable system for treprostinil a real world patient experience study |
| url | https://doi.org/10.1177/2045894020907881 |
| work_keys_str_mv | AT shelleyshapiro implantablesystemfortreprostinilarealworldpatientexperiencestudy AT robertcbourge implantablesystemfortreprostinilarealworldpatientexperiencestudy AT pattipozella implantablesystemfortreprostinilarealworldpatientexperiencestudy AT davidfharris implantablesystemfortreprostinilarealworldpatientexperiencestudy AT erickhborg implantablesystemfortreprostinilarealworldpatientexperiencestudy AT andrewcnelsen implantablesystemfortreprostinilarealworldpatientexperiencestudy |